Can ZIVO BIOSCIENCE INCORPORATED (OTCMKTS:ZIVO)’s Tomorrow Be Different? The Stock Had Decline in Shorts

January 10, 2018 - By Vivian Currie

The stock of ZIVO BIOSCIENCE INCORPORATED (OTCMKTS:ZIVO) registered a decrease of 94.51% in short interest. ZIVO’s total short interest was 500 shares in January as published by FINRA. Its down 94.51% from 9,100 shares, reported previously.

The stock decreased 12.23% or $0.0108 during the last trading session, reaching $0.0775. About shares traded. Zivo Bioscience, Inc. (OTCMKTS:ZIVO) has 0.00% since January 10, 2017 and is . It has underperformed by 16.70% the S&P500.

Zivo Bioscience, Inc., together with its subsidiaries, focuses on the research and identification of natural bioactive ingredients derived from its proprietary algal cultures. The company has market cap of $10.92 million. The firm intends to license and sell its natural bioactive ingredients to animal, food, dietary supplement, and medical food manufacturers; and license its bioactive molecules as lead compounds or templates for synthetic variants intended for therapeutic applications. It currently has negative earnings. It is also involved in developing, manufacturing, marketing, and selling tests that allow individuals to optimize their health and identify future health risks, as well as provides insurers, employers, and healthcare providers with timely information to intervene with wellness programs, fitness regimes, or other preventative measures.

More notable recent Zivo Bioscience, Inc. (OTCMKTS:ZIVO) news were published by: Globenewswire.com which released: “ZIVO Bioscience, Inc. Executes Definitive Agreement With NutriQuest, Commences …” on April 26, 2017, also Marketwired.com with their article: “ZIVO Bioscience, Inc. (OTCQB: ZIVO) — Effective Monday, November 10 — Health …” published on November 10, 2014, Globenewswire.com published: “ZIVO Bioscience Subsidiary Wellmetris Selected to Present at Biotech Showcase …” on January 08, 2018. More interesting news about Zivo Bioscience, Inc. (OTCMKTS:ZIVO) were released by: Globenewswire.com and their article: “ZIVO Bioscience, Inc. Midyear CEO Report – May 2017” published on May 02, 2017 as well as Globenewswire.com‘s news article titled: “ZIVO Bioscience, Inc. Kicks Off Final Phase of Bovine Mastitis Study” with publication date: September 11, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: